Compare places

Two or three clusters, read side by side across sectors, research, companies, capital, infrastructure, government designations and UKIZ relevance. There is no score and no ranking: British clusters are different from one another, not better or worse than one another.

Choose up to three clusters

Side by side

Dimension	CambridgeEast of England	LondonGreater London	Leeds & West YorkshireYorkshire and the Humber
Sectors	Life Sciences, Semiconductors, Engineering Biology, Artificial Intelligence Supporting: Quantum Technologies, Advanced Materials, AgriTech & FoodTech, Digital Technologies	Financial Technology, Artificial Intelligence, Creative Industries, Digital Technologies Supporting: Life Sciences, Quantum Technologies, Engineering Biology, Defence & Security	Life Sciences, Digital Technologies, Financial Technology Supporting: Artificial Intelligence, Advanced Manufacturing, Creative Industries
Research	University of Cambridge Wellcome Sanger Institute MRC Laboratory of Molecular Biology	Imperial College London University College London King's College London Queen Mary University of London The Alan Turing Institute The Francis Crick Institute	University of Leeds
Companies	Cambridge semiconductor and processor IP cluster	Not recorded on the map.	Leeds health data and digital health cluster
Infrastructure	Babraham Research Campus Cambridge Science Park University and institute laboratories, genomics and biomedical campus facilities, and semiconductor design capability.	Digital Catapult Connected Places Catapult Cell and Gene Therapy Catapult Level39 University laboratories, teaching hospitals, data centre and compute capacity, and the densest transport network in the country.	Not recorded on the map. Health data infrastructure, teaching hospitals and university research facilities.
Capital	Specialist deep tech and life science funds, university-linked funds, and corporate partners; strong at seed, thinner at growth stage relative to demand.	London venture and growth capital ecosystem Venture, growth and public market capital at a scale unmatched elsewhere in Europe, plus corporate venture arms and international investors with UK offices.	Financial services depth locally, but early-stage health technology capital remains limited.
Government programmes	No place-based designation recorded.	No place-based designation recorded.	No place-based designation recorded.
What exists	Extreme research density for its size: life sciences and genomics, semiconductor and processor IP, engineering biology and AI, with a mature spin-out culture and specialist investors who understand long timelines.	Four research-intensive universities, the deepest venture and growth capital pool in Europe, financial regulators, the largest concentration of applied AI companies in the UK and a global-scale creative production economy — all within one travel-to-work area.	National health data organisations, medical technology, a large financial and professional services base and a research university with data and materials strength.
What's missing · UKIZ interpretation	Ownership retention. Discovery and early company formation work; the Series B onward stage frequently transfers ownership overseas. Laboratory and scale-up space, power and housing also constrain growth.	Circulation. Capital, talent and corporate demand concentrate in London rather than flowing outward, so capability elsewhere in Britain competes for attention with opportunities on the investor's doorstep. Cost also pushes production and scale-up activity out without a route back in.	A clear route for companies to work with health data at scale, and clinical adoption pathways that move faster than pilot projects.
What could connect · UKIZ interpretation	Cambridge discovery connected to UK manufacturing and biomanufacturing capacity, and to later-stage domestic capital, so that value created here is realised here rather than acquired out of the country.	London as the demand and capital node of a national network: investors, corporate buyers and regulators deliberately connected to complementary manufacturing, materials and energy capability in the North, Midlands, Scotland and Wales.	Leeds health data capability connected to Manchester clinical research and to medical technology manufacturing, giving companies discovery, evidence and production in one region.
UKIZ relevance	Cambridge produces intellectual property at a rate few places match, and loses ownership of too much of it at Series B. The proposed Oxford–Cambridge zone concentrates on commercialisation and retention rather than on more discovery.	London's problem is not capability, it is direction of travel: capital and talent gravitate here rather than circulating. The proposed London zone focuses on using that density to fund and buy from capability elsewhere in Britain.	Health data at population scale is a national asset. The proposed Manchester mission and Leeds capability are complementary rather than competing.
Last verified	15 August 2026	15 August 2026	15 August 2026

Proposed by UKIZ · not a government designation

Back to the map →Methodology →